Translational Development Acquisition, ProLogium to Combine in $3.8 Billion Transaction

MT Newswires Live
05/27

Translational Development Acquisition (TDAC), a blank-check company, and ProLogium said Wednesday they have agreed to a business combination valuing ProLogium at about $3.8 billion on a pre-money, net cash-free basis.

ProLogium will seek funding by a combination of Translational's cash in trust and proceeds from a private investment in public equity deal, the companies said.

The boards of both companies have approved the deal, which is set to close in H2 and would result in the combined company ProLogium Technology becoming a Nasdaq-listed company under the ticker symbol PRLG, according to the statement.

The transaction is anticipated to fund the scaling of ProLogium's production of its fourth-generation batteries and the construction of a gigafactory in Dunkirk, France, the companies said.

ProLogium aims to mass produce solid-state battery technology with its proprietary lithium ceramic battery platform, the companies added.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10